STERIS’ (TSE:STE – Free Report) – Investment analysts at Raymond James lowered their FY2025 EPS estimates for shares of STERIS’ in a research note issued on Wednesday, March 12th. Raymond James analyst M. Barth now anticipates that the company will post earnings per share of $0.64 for the year, down from their previous forecast of $0.76. Raymond James also issued estimates for STERIS’’s FY2029 earnings at $0.68 EPS.
Several other research analysts have also commented on the stock. Cormark raised shares of STERIS’ to a “moderate buy” rating in a report on Monday, January 6th. Atb Cap Markets raised shares of STERIS’ to a “strong-buy” rating in a report on Sunday, December 22nd.
STERIS’ Price Performance
STERIS’ Company Profile
STERIS’s MISSION IS TO HELP OUR CUSTOMERS CREATE A HEALTHIER AND SAFER WORLD by providing innovative healthcare and life science product and service solutions around the globe by providing innovative healthcare and life science product and service solutions around the globe.
Featured Articles
- Five stocks we like better than STERIS’
- How to Invest in the Best Canadian Stocks
- 3 Undervalued Stocks You Can Buy at a Discount Now
- 3 Best Fintech Stocks for a Portfolio Boost
- AMD Stock: Can the PC Refresh Cycle Spark a Rally?
- How to Use Stock Screeners to Find Stocks
- Micron Stock Spikes 7%—3 Key Catalysts Behind the Move
Receive News & Ratings for STERIS’ Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for STERIS’ and related companies with MarketBeat.com's FREE daily email newsletter.
